Creation of a Clinical Database on Primary Nervous System Tumors

NCT04516720 | Recruiting

• 1 other identifier: PROICM 2017-01 BNO
• Study Type: observational
• Target: 1,700
• Locations: 1 country
• Sites: 1

Brief Summary

the creation of a clinical database including data for all PCNST patients is of high interest. This database will allow us to develop clinical studies on:

• The clinical, radiological and biological presentation of tumors, the impact of oncological treatments and the evaluation of survival for the different subtypes of Primary central nervous system tumors (PCNST). This is particularly important for rare histological subtypes of PCNST for which the current knowledge is scarce;
• Clinical, radiological and biological factors predictive of tumor response to treatments;
• Prognostic factors.

Conditions

Nervous System Tumor

Keywords

Primary central nervous system tumors; clinical database

Outcome Measures

Primary Outcomes (1)

• Establish an exhaustive database of patients treated for a Primary central nervous system tumors at the Montpellier Cancer Institute, whatever the histological subtype and the oncological treatment

  collection of clinical data in the medical record

  From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Secondary Outcomes (3)

• Realization of clinical studies specific to certain histological subtypes to be carried out on the clinical, radiological and biological presentation of patients, specific oncological treatments and toxicities, prognostic factors and survival data

  From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

• To allow the realization of epidemiological studies specific to certain histological subtypes

  From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

• To facilitate the identification of patients for inclusion in French or European retrospective studies

  From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Study Arms (1)

Primary Nervous System Tumors arm

The information letter will be delivered by the investigator physician to the patients to inform them on the study, its implementation and their complete freedom to participate or not. Clinical Data and Questionnaires: 1. For the retrospective part * Patient identification based on data from the Medical Information Department (DIM) of the ICM; * Verification of the eligibility criteria; * Inclusion of patients in a coded form in BDD-NO; * Implementation of the database with the data already collected (as an coded EXCEL file) in specific studies (some patients are included in several of these studies): study of diffuse low grade gliomas, study on anaplastic gliomas, study on the place of Bevacizumab in high-grade gliomas, clinical database created * Collection of clinical data from each patient's medical record 2. For the prospective part * Inclusion of patients in a coded form in BDD-NO; * Collection of clinical data from each patient's medical record.

Other: data collection

Interventions

data collection OTHER

Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death

Primary Nervous System Tumors arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

all patient with Primary central nervous system tumors and treated at the Montpellier Cancer Institute

You may qualify if:

• Adult patient aged ≥ 18, no age limit;
• Diagnosis of Primary central nervous system tumors ;
• Patient treated at the Montpellier Cancer Institute, whatever the treatment received (systemic treatment, radiotherapy or exclusive supportive care);
• For the retrospective part of the study, patient first treated at the Montpellier Cancer Institute between January 1rst, 2004 and the beginning of the prospective part;
• Patient information for the retrospective (patient still alive at the beginning of the study) and prospective study.

You may not qualify if:

• Secondary lesions of the central nervous system;
• Patient not affiliated to a social protection scheme;
• Subject under tutelage, curatorship or safeguard of justice.

Sponsors & Collaborators

• Institut du Cancer de Montpellier - Val d'Aurelle: lead

Study Sites (1)

Icm Val D'Aurelle

Montpellier, Herault, 34298, France

RECRUITING

Related Publications (12)

• Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug;114(2):97-109. doi: 10.1007/s00401-007-0243-4. Epub 2007 Jul 6.

  PMID: 17618441 RESULT

• Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.

  PMID: 27157931 RESULT

• Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015 Oct;17 Suppl 4(Suppl 4):iv1-iv62. doi: 10.1093/neuonc/nov189. Epub 2015 Oct 27. No abstract available.

  PMID: 26511214 RESULT

• Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rossler K, Hainfellner JA. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009 Dec;95(3):401-411. doi: 10.1007/s11060-009-9938-9. Epub 2009 Jun 28.

  PMID: 19562257 RESULT

• Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, Tourdias T, Kantor G, Maire JP, Vital A, Loiseau H; Gironde TSNC Registry Group. Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007. Neuro Oncol. 2011 Dec;13(12):1370-8. doi: 10.1093/neuonc/nor120. Epub 2011 Oct 6.

  PMID: 21980160 RESULT

• Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J, Brandes A; RARECARE working group. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012 Jul;48(10):1532-42. doi: 10.1016/j.ejca.2011.12.013. Epub 2012 Jan 7.

  PMID: 22227039 RESULT

• Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daude H, Tretarre B, Bauchet F, Duffau H, Taillandier L, Bauchet L. Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol. 2017 Feb;131(3):525-546. doi: 10.1007/s11060-016-2318-3. Epub 2016 Nov 16.

  PMID: 27853959 RESULT

• DeAngelis LM. Brain tumors. N Engl J Med. 2001 Jan 11;344(2):114-23. doi: 10.1056/NEJM200101113440207. No abstract available.

  PMID: 11150363 RESULT

• Jakola AS, Skjulsvik AJ, Myrmel KS, Sjavik K, Unsgard G, Torp SH, Aaberg K, Berg T, Dai HY, Johnsen K, Kloster R, Solheim O. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017 Aug 1;28(8):1942-1948. doi: 10.1093/annonc/mdx230.

  PMID: 28475680 RESULT

• Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, Pallud J, Peruzzi P, Baron MH, Kujas M, Guyotat J, Guillevin R, Frenay M, Taillibert S, Colin P, Rigau V, Vandenbos F, Pinelli C, Duffau H; French Reseau d'Etude des Gliomes. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg. 2013 Jun;118(6):1157-68. doi: 10.3171/2013.1.JNS121. Epub 2013 Mar 15.

  PMID: 23495881 RESULT

• Boetto J, Bertram L, Moulinie G, Herbet G, Moritz-Gasser S, Duffau H. Low Rate of Intraoperative Seizures During Awake Craniotomy in a Prospective Cohort with 374 Supratentorial Brain Lesions: Electrocorticography Is Not Mandatory. World Neurosurg. 2015 Dec;84(6):1838-44. doi: 10.1016/j.wneu.2015.07.075. Epub 2015 Aug 14.

  PMID: 26283485 RESULT

• Mandonnet E, Wager M, Almairac F, Baron MH, Blonski M, Freyschlag CF, Barone F, Fontaine D, Pallud J, Hegi M, Viegas C, Zetterling M, Spena G, Goodden J, Rutten GJ, Taillandier L, Foroglu N, Darlix A, Skrap M, Martino J, von Campe G, Madadaki C, Gayat E, de Witt Hamer P, Gil Robles S, Sarubbo S, Santarius T, Bello L, Forster MT, Duffau H. Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step? Neurooncol Pract. 2017 Dec;4(4):241-247. doi: 10.1093/nop/npw031. Epub 2017 Jan 17.

  PMID: 31386020 RESULT

MeSH Terms

Conditions

Nervous System Neoplasms

Interventions

Data Collection

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Amélie DARLIX, MD

  Institut régional du Cancer Montpellier

  STUDY CHAIR

Central Study Contacts

Aurore MOUSSION, MD

CONTACT

04 67 61 31 02; DRCI-icm105@icm.unicancer.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 11, 2020
• First Posted: August 18, 2020
• Study Start: January 1, 2018
• Primary Completion (Estimated): January 1, 2035
• Study Completion (Estimated): January 1, 2039
• Last Updated: February 12, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)